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Abstract 
Persistent  non-valvular  atrial  fibrillation
(NVAF) is associated with an increased risk
of cardiovascular events such as stroke, and
its  rate  is  expected  to  rise  because  of  the
ageing  population.  The  absolute  rate  of
stroke depends on age and comorbidity. Risk
stratification  for  stroke  in  patients  with
NVAF  derives  from  populations  enrolled  in
randomized clinical trials. However, partici-
pants in clinical trials are often not represen-
tative of the general population. Many stroke
risk stratification scores have been used, but
they do not include transthoracic echocardio-
gram  (TTE),  pulsate  wave  Doppler  (PWD)
and  tissue  Doppler  imaging  (TDI),  simple
and non- invasive diagnostic tools. The role
of TTE, PWD and TDI findings has not been
previously determined. Our study goal was to
determine the association between TTE and
PWD findings and stroke prevalence in a pop-
ulation of NVAF prone outpatients. 
Patients were divided into two groups: P
for stroke prone and F for stroke free. There
were no statistically significant differences
between the two groups concerning cardio-
vascular  risk  factors,  age  (p=0.2),  sex
(p=0.2), smoking (p=0.3), diabetes (p=0.1)
and hypercholesterolemia (p=0.2); hyperten-
sion was statistically significant (p<0.001).
There  were  statistically  significant  differ-
ences  concerning  coronary  artery  disease,
previous acute myocardial infarction (AMI)
(p<0.05)  and  non-  AMI  coronaropathy
(p<0.04), a higher rate being in the P group.
Concerning echo-Doppler findings, a higher
statistically significant rate of left ventricular
hypertrophy (LVH) (p<0.05) and left ventric-
ular  diastolic  dysfunction  (p<0.001)  was
found in the P group and dilated left atrium
(p<0.04) in the F group, the difference was
not  significant  for  mitral  regurgitation
(p=0.7). Stroke prone NVAF patients have a
higher rate of hypertension, coronary artery
disease, with and without AMI, LVH and left
ventricular diastolic dysfunction, but not left
atrial dilatation. M-B mode echocardiography
and PWD examination help to identify high-
risk  stroke  patients  among  NVAF  subjects;
therefore, they may help in the selection of
appropriate therapy for each patient.
Introduction
Persistent  non-valvular  atrial  fibrillation
(NVAF), the most common cardiac arrhyth-
mia, is associated with an increased risk of
heart failure and cardiovascular events such
as stroke: its rate is expected to rise
1 because
of the ageing population. The absolute rate of
stroke  depends  on  age  and  comorbidity.
2-4
Many studies have attempted to define clini-
cal  criteria  that  can  be  used  to  classify
patients  affected  by  AF  as  being  at  low  or
high risk,
2,5 in order to choose the therapy
with  the  best  risk/effectiveness  profile.
1,6-9
Risk stratification for stroke in patients with
AF  derives  from  studying  populations
enrolled  in  randomized  clinical  trials.
5,6
However,  participants  in  clinical  trials  are
slightly younger, more likely to be male, and
generally have fewer comorbidities than peo-
ple seen in the "real world" of clinical prac-
tice.
10 AF prone patients, <65 yrs, without a
history  of  hypertension,  previous  stroke  or
transient  ischemic  attack,  or  diabetes,  are
classified  as  a  low-risk  population.
3 Many
stroke  risk  stratification  scores  have  been
used, but interestingly, available risk scores
do  not  include  any  variable  derived  from
transthoracic echocardiogram (TTE), pulsate
wave  Doppler  (PWD)  and  tissue  Doppler
imaging  (TDI),  simple  and  non-invasive
diagnostic  tools.  Transesophageal  echocar-
diographic  examination  (TEE)  is  also  very
useful,
11,12 but  it  is  partially  invasive  and
expensive. Furthermore, in NVAF outpatients
with no recent history of embolism, TEE is of
limited value in assessing stroke risk
13 and
its  role  in  detecting  cardiac  sources  of
embolism in elderly stroke patients needs to
be  better  clarified.
14 3D  echo  is  useful  in
these patients, but it is not available every-
where and its outcome needs to be validat-
ed.
15 A  new  generation  echo  system  allows
transthoracic  detection  of  left  atrial
appendage thrombi and accurate determina-
tion of left atrial appendage function in most
patients with a neurological deficit.
16 In addi-
tion, the prognostic implications of sponta-
neous  contrast  in  NVAF  patients  are
unknown.
17 Routine  management  of  NVAF
includes  the  primary  stroke-preventive
measures;  echocardiogram  has  been  an
important adjunctive tool in the evaluation of
AF.
18 Left  ventricular  systolic  dysfunction
impairs left atrial function parameters and it
is supposed to increase left atrial thrombus
rate in patients with chronic NVAF
19 and in
elderly patients, E/A <0.5 and a low atrial fill-
ing  fraction  were  markers  of  increased  AF
risk, suggesting that impaired atrial filling
may,  over  time,  precede  AF  onset.
20-22
Specifically, the role of TTE, PWD and TDI
findings has not been previously determined.
Our study goal was to determine the associa-
tion  between  TTE,  PWD,  TDI  findings  and
stroke  prevalence  in  a  population  of  NVAF
prone outpatients. 
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Patients
We  studied  230  consecutive  patients
affected by NVAF referred to our outpatient
unit  for  cardiological  examination.  All
patients  gave  informed  consent  to  be
enrolled in our study. Recruitment started in
January 2003 and lasted one year. All patients
underwent  full  cardiological  examination,
clinical history collection, electrocardiogram,
M-B mode echocardiogram and PWD exami-
nation. Exclusion criteria were: valvular AF,
smoking or left atrial thrombi and bad tho-
racic view. Persistent AF diagnosis was per-
formed when the arrythmia was detected by
positive electrocardiogram at enrolment and
the time-standing of NVAF was over one year.
Two hundred and thirty patients were includ-
ed. Table 1 reports the clinical characteristics
of the study population. Patients were classi-
fied as prone to stroke from a documented
history of stroke with assessment by cerebral
contrast  tomography  scan.  All  patients
enrolled in our study underwent anticoagula-
tion therapy twice monthly monitored by INR. 
Electrocardiographic evaluation
Electrocardiograms  were  performed  by
Esaote-Biomedica  Archimed  4210  12  lead
electrocardiography, the criteria for AF diag-
nosis are replacement of P waves by rapid
oscillations of fibrillatory waves that vary in
size, shapes and timing, associated with an
irregular ventricular response. 
TTE was performed by GE Vivid 3 expert, a
phased-array echo-Doppler system equipped
with a 2.5 Hz probe. All patients were exam-
ined  in  the  left  lateral  recumbent  position
using standard parasternal, long-axis, short-
axis,  and  apical  views.  M-mode  recordings
were obtained, and left ventricular diastolic
diameter, as well as septal and posterior wall
thickness  were  measured.  Left  ventricular
mass index (LVMI) was obtained by dividing
the  left  ventricular  mass  by  body  surface
area. Left ventricular hypertrophy (LVH) was
defined as an LVMI >110 g/m
2 for females and
>134 g/m
2 for males.
The left atrial (LA) size was determined as
the  diameter  in  parasternal  long-axis  and
short-axis  view,  directly  on  B-mode  then
checked  on  M-mode,  at  end  systole,  from
leading edge to leading edge. Diameters and
volumes  of  left  atrium  and  ventricle  deter-
mined  by  single  beam  echocardiography
demonstrated a good correlation with hemo-
dynamic  findings.
23,24 Echocardiographic
measurements were obtained at end-expira-
tion. All analyses were based on the average
obtained by five beat measurements. Intra-
and  inter-observer  variability  was  deter-
mined: two study investigators repeated each
measurement  in  10  randomly  chosen
patients to ensure that a correlation coeffi-
cient of 0.9 was obtained by linear regression
analysis.  Mitral  inflow  characteristics  were
analyzed  using  Doppler  echocardiography.
Mitral  inflow  velocities  were  measured  at
end-expiration at the level of the tips of the
mitral  leaflets  on  the  four-chamber  view,
using pulsed Doppler, performed at end-expi-
ration. The Doppler beam was aligned to pro-
duce the narrowest possible angle between
the beam and the blood flow vector. 
The peak velocity during early filling (E),
the deceleration time from peak early filling
and isovolumic relaxation time, extrapolated
to the baseline were measured. Diastolic dys-
function  was  assessed  when  the  following
two  parameters  were  checked  together:
mitral flow, E wave DT >220 m.sec and IVRT
>105  m.sec.  Myocardial  tissue  characteris-
tics  were  analyzed  using  pulsed  Doppler
echocardiography.  Tissue  velocities  were
measured at end-expiration at the ventricu-
lar lateral mitral annulus level, on four-cham-
ber view.
25 The peak velocity during early fill-
ing  (Em)  extrapolated  to  the  baseline  was
measured. 
Mitral  regurgitation  was  assessed  by
Doppler color flow jet area inside the left atri-
um.  Clinical  predictors  evaluated  included
patient demographic data such as age, gen-
der and body surface area; co-existent risk
factors were hypertension, diabetes, hyperc-
holesterolemia and smoking. Coronary artery
diseases were assessed by medical history of
acute  myocardial  infarction  (AMI)  or  non-
AMI coronaropathy only if supported by cardi-
ological records.
Statistical analysis
The  relationship  between  stroke  prone
patients (P group) and stroke free patients (F
group) for all above-mentioned echo findings
was assessed using the χ
2 test for non-para-
metric analysis and the Student’s t-test for
parametric analysis. p<0.05 was considered
significant.  Multivariate  analysis  was  per-
formed.
Results
Thirty-nine of the 230 patients studied had a
history of stroke. Stroke prone patients were
included  in  the  P  group,  and  stroke  free
patients in the F group. Mean age was 76±6 yrs
in the P group and 77±3 yrs in the F group,
20/39  patients  (51%)  were  males  in  the  P
group, and 86/191 were males (45%) in the F
group, 7/39 patients (17.9%) in the P group
and  31/191  patients  (16.2%)  in  the  F  group
were smokers, 6/39 patients (15.4%) in the P
group  and  26/191  patients  (13.6%)  in  the  F
group were affected by diabetes, 9/39 patients
(23.1%)  in  the  P  group  and  37/191  patients
(19.4%) in the F group were affected by hyper-
cholesterolemia, 28/39 patients (71.7%) were
hypertensive  in  the  P  group  and  95/191
patients (49.7%) in the F group. Differences
between the two groups for age (p=0.2), sex
(p=0.2),  smoking  (p=0.3),  diabetes  (p=0.1)
and  hypercholesterolemia  (p=0.2)  were  not
statistically significant. There was a statisti-
cally significant difference for the hyperten-
sion rate between the P group (71.7%) and the
F group (49.7%) (p<0.001). Previous AMI was
detected  in  29/230  patients  (12.6%);  9/39
patients  (20.5%)  in  the  P  group  and  20/191
patients (10.4%) in the F group and the differ-
ence  was  statistically  significant  (p<0.05).
Non-AMI coronary artery disease was detected
in 74/230 patients (32.2%), 18/39 (46.1%) in
the P group and 56/191 patients (29.3%) in the
F group and the difference was statistically sig-
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Table 1. Study population: clinical characteristics.
P group F group p value
Age (years) 76±6 77±3 p=0.2
Male 20/39 (51%) 86/191 (45%)  p=0.2
On smoke 7/39 (17.9%)  31/191 (16.2%)  p=0.3
On diabetes 6/39 (15.4%)  26/191 (13.6%)  p=0.1
On hypercholesterolemia 9/39 (23.1%)  37/191 (19.4%)  p=0.2
On hypertension 28/39 (71.7%)  95/191 (49.7%)  p<0.001
P: atrial fibrillation prone; F: atrial fibrillation free.
Table 2. Study population: coronary artery diseases.
P group F group p value
AMI CAD 9/39 (20,5%)  20/191(10.4%)  p<0.05
nonAMI CAD 18/39 (46.1%)  56/191(29.3%)  p<0.04
P: atrial fibrillation prone; F: atrial fibrillation free; CAD: coronary artery disease; AMI: acute myocardial infarction.Article
[page 6] [Heart International 2009; 4:e2]
nificant  (p<0.04)  (Table  2).  LVH  was  diag-
nosed  in  87/230  patients  (37.8%);  10/39
patients  (40.3%)  in  the  P  group  and  77/191
patients (256%) in the F group, and the differ-
ence was statistically significant (p<0.05) and
not dependent on the hypertension rate. Left
ventricular  diastolic  dysfunction  occurred  in
62/230 patients (26.9%), 16/39 patients (41%)
in the P group and 46/191 patients (24%) in
the F group and the difference was statistically
significant  (p<0.001)  and  not  dependent  on
the  hypertension  rate.  Left  atrium  diameter
was >40 mm in 80/230 patients (34.7%), 8/39
patients (20.5%) in the P group and in 72/191
patients (37.6%) in the F group and the differ-
ence  was  statistically  significant  (p<0.04).
Mitral  regurgitation  was  detected  in  75/230
patients (32.6%), 12/39 patients (30.7%) in the
P group and 63/191 patients (33%) in the F
group but the difference was not statistically
significant (p=0.7) (Table 3). Significant sta-
tistical differences were preserved also after
correction for sex and age.
Discussion
The most important finding of this study is
that coronary artery disease, LVH and diastolic
dysfunction evaluated by TTE are associated
with  a  higher  prevalence  of  stroke  among
NVAF patients.
22
A previous risk stratifier had been identified
in  large  randomized  clinical  trials;  however,
the  population  enrolled  in  these  studies  is
often not representative of the general popula-
tion. If the AF rate is expected to rise
1 it is use-
ful to evaluate the impact of simple and non-
invasive  diagnostic  tools  such  as  TTE,  PWD
and  TDI,  in  predicting  stroke  in  persistent
NVAF. Risk stratification helps in the prognosis
and in the selection of appropriate candidates
for different therapies such as aspirin, war-
farin,  direct  thrombin  inhibitors  or  electric
therapy.
7,9,26 Our patients were a sample of the
general  population  affected  by  PNVAF,  while
participants in trials are slightly younger, more
likely  to  be  male,  and  generally  have  fewer
comorbidities than those in our study popula-
tion.
1,3,5,6,12,13,26 Our two patient groups were sim-
ilar for age and sex, so the absolute rate of
stroke  depends  only  on  comorbidity.  All  risk
scores we considered are affected by a selec-
tion  bias;  therefore,  risk  factors  previously
used for scoring, such as systolic blood pres-
sure,  diabetes,  smoking,  prior  myocardial
infarction need to be validated. In our patients,
common risk factors such as diabetes, hyperc-
holesterolemia
27 and  smoking  were  similar
between  the  two  groups;  therefore,  in  our
study of an outpatient population, they seemed
not to be so relevant. On the other hand, an
important  cardiovascular  risk  factor  such  as
hypertension is more frequent, in a statistical-
ly  significant  way,  among  our  stroke  prone
patients.  Concerning  comorbidity,  a  positive
clinical  history  for  previous  AMI,  associated
with  a  diagnostic  tool  confirmation,  was
detected more often, in a statistically signifi-
cant  way,  among  stroke  prone  patients.  The
same  occurred  for  non-AMI  coronary  artery
disease.  Therefore,  it  is  clear  that  previous
coronary artery disease, regardless of clinical
presentation, is a strong predictor of stroke.
Concerning  the  echocardiographic  contribu-
tion to stroke prognostic stratification, we con-
sidered four parameters. First, LVH is more fre-
quent in a statistically significant way among
stroke  prone  patients,  as  in  the  LIFE  study
which assessed a lower stroke death and acute
myocardial infarction rate, in a composite end-
point, in patients affected by LVH.
28 Secondly,
left atrium diameter >40 mm is more frequent,
in a statistically significant way, among stroke
free patients: we know that a dilated left atri-
um  is  an  important  cardiac  source  of
embolism, but this seems not to be important
in NVAF patients.
18,19 Thirdly, mitral regurgita-
tion assessment may have proved to be protec-
tive against stroke in many studies, but our
study does not support this. We observed all
mild mitral regurgitations and we can deter-
mine  that  this  kind  of  mitral  regurgitation
does not play a role in preventing stroke.
29,30
Fourthly, the rate of LV diastolic dysfunction
was higher among stroke prone patients, in a
statistically significant way. LV diastolic dys-
function impairs left atrial function parame-
ters and is supposed to increase the frequency
of  LA  thrombus  in  patients  with  chronic
NVAF.
19,21 We think that TEE is a very useful
tool,
12 but it is partially invasive and expensive,
although TEE is considered the gold standard
for excluding left atrial (LA) thrombi,
31 perhaps
in  non-rheumatic  AF  outpatients,  with  no
recent history of embolism, TEE is of limited
value in assessing stroke risk
13 and the role of
TEE in detecting cardiac sources of embolism
in elderly stroke patients needs to be better
clarified.
14 In addition, the prognostic implica-
tions of spontaneous contrast in patients with
NVAF are unknown.
17
All available risk scores must include some
diagnostic tools; therefore, it is correct to ana-
lyze  every  single  tool’s  prognostic  power,  to
predict stroke and to improve primary stroke
prevention measures.
Conclusions
Stroke prone NVAF patients have a higher
rate of hypertension, coronary artery disease,
with and without AMI, LVH and left ventricular
diastolic dysfunction, but not left atrial dilata-
tion.  M-B  mode  echocardiography  and  PWD
examination help to identify high-risk stroke
patients among NVAF subjects; therefore, they
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